Details for New Drug Application (NDA): 206106
✉ Email this page to a colleague
NDA 206106 describes THIAMINE HYDROCHLORIDE, which is a drug marketed by Abraxis Pharm, Bel Mar, Caplin, Dell Labs, Dr Reddys, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Hospira, Luitpold, Mylan Institutional, Parke Davis, Sagent Pharms Inc, Watson Labs, West-ward Pharms Int, and Wyeth Ayerst, and is included in seventeen NDAs. It is available from thirteen suppliers. Additional details are available on the THIAMINE HYDROCHLORIDE profile page.
The generic ingredient in THIAMINE HYDROCHLORIDE is thiamine hydrochloride. There are seven drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the thiamine hydrochloride profile page.
The generic ingredient in THIAMINE HYDROCHLORIDE is thiamine hydrochloride. There are seven drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the thiamine hydrochloride profile page.
Summary for 206106
| Tradename: | THIAMINE HYDROCHLORIDE |
| Applicant: | Sagent Pharms Inc |
| Ingredient: | thiamine hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 206106
Suppliers and Packaging for NDA: 206106
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| THIAMINE HYDROCHLORIDE | thiamine hydrochloride | INJECTABLE;INJECTION | 206106 | ANDA | Sagent Pharmaceuticals | 25021-500 | 25021-500-02 | 25 VIAL in 1 CARTON (25021-500-02) / 2 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 100MG/ML | ||||
| Approval Date: | Dec 1, 2017 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
